Evaxion Biotech A/S, hereinafter “Evaxion” or the “Company”, a clinical research-focused biotechnology company specializing in the development powerful vaccines based on its AI immunology platform, AI-Immunology™, is pleased to announce the successful completion of a series of large-scale studies investigating infections in non-rodent animals and targeting to test the antigens of EVX-B1, Evaxion's preclinical vaccine candidate against Staphylococcus aureus (S. aureus). In animal studies, EVX-B1 antigens significantly reduced disease burden. Currently, the two companies are in the discussion phase to determine the way forward.

Birgitte Rønø, Scientific Director at Evaxion, expressed her enthusiasm: “We are delighted with the encouraging data and believe that the antigens in our vaccine, EVX-B1, have potential for effectiveness in human trials. 'To be human. This is an important milestone that previous vaccine trials have failed to achieve so far. »

There is no vaccine against  S. aureus that can be used in humans. This pathogen can cause infections in several organs and tissues which can be very severe or even fatal. Those most at risk are those with chronic illnesses and patients undergoing surgical procedures. Furthermore, the presence of strains of S .  antibiotic-resistant aureus further limits the available treatment options. According to the Centers for Disease Control and Prevention (CDC), 120,000  S. aureus -associated bloodstream infections occur in the United States each year.

Three separate studies involving large animals other than rodents were carried out, with the following conclusions:

• EVX-B1 vaccine antigens significantly reduced the bacterial load of S .  aureus in a surgical site infection model
• Induction of significant antigen-specific antibody titers in all vaccinated animals
• Ability of antigens to induce a protective immune response in animals colonized by  S. aureus , reproducing the situation in humans
• Ability of immunized blood to neutralize strains of  S. aureus clinically relevant in a whole blood bactericidal capacity test, which is promising for translational readout of the assay in early clinical development

About EVX-B1

The EVX-B1 antigens were designed using Evaxion's AI-Immunology™ platform. AI-Immunology™ enabled the identification of novel Staphylococcus aureus antigens , paving the way for the development of a vaccine with broad potential for protection against clinically relevant strains of S. aureus .

About  Staphylococcus  aureus

According to the CDC, S . aureus colonizes around 30% of the human population without causing any damage. Nevertheless , S. aureus can also cause potentially serious and even fatal infections. One of the most serious conditions is bacteremia, or septicemia, in which bacteria spread through the bloodstream. This pathogen can also cause pneumonia, endocarditis, and osteomyelitis (infections of the lung alveoli, heart valves, and bones, respectively). Those most at risk are those with chronic illnesses such as diabetes, patients in intensive care units, patients who have undergone certain surgical procedures, and patients with medical devices inserted into the body. The presence of antibiotic-resistant strains of S. aureus , particularly methicillin-resistant S. aureus (MRSA), further limits treatment options. In the United States, nearly 120,000 bloodstream infections and 20,000 deaths were associated with S. aureus in 2017.

About EVAXION

Evaxion Biotech A/S is a pioneering biotechnology company driven by its artificial intelligence platform: AI-Immunology™. Evaxion's proprietary and scalable AI predictions harness the potential of artificial intelligence to decode the human immune system and develop new immunotherapies for cancer, bacterial diseases and viral infections. Using AI-Immunology™, Evaxion has developed a pipeline of novel personalized clinical-stage oncology vaccines, and a pre-clinical pipeline for infectious, bacterial and viral diseases, which address many unmet medical needs. Evaxion is committed to transforming patients' lives by offering them innovative and targeted therapeutic options. For more information on Evaxion and its revolutionary AI-Immunology™ platform, as well as its vaccine pipeline, visit  our website .

Forward-looking statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target”, “believe”, “expect”, “hope”, “aim”, “intend”, “may”, “could”, “anticipate”, “consider”, “ continue”, “estimate”, “forecast”, “potential”, “predict”, “project”, “will”, “may have”, “probable”, “should”, “would”, “could” and Other words and terms of similar meaning characterize forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks relating to: our financial condition and additional capital requirements; our development work; the cost and success of our product development and preclinical and clinical testing activities; the commercialization of any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties, including for the conduct of clinical trials and manufacturing of products; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee issues and growth management; our ADSs and ordinary shares; the impact of international economic, political, legal, regulatory, social and commercial factors, including inflation, and the effects on our business of the ongoing global COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a more in-depth discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), available at address  www.sec.gov . We undertake no obligation to update any forward-looking statements, except as required by law.

 

Source: globenewswire.com

Report Abuse